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*C. Difficile infections were excluded.
138 Poster Session-II(HLA match, n5 72; mismatch, n5 16), which contained a mean of
4.0 106 CD341 cells/kg (0.9–10.9  106 cells/kg) and 3.4  108
CD31 cells/kg (1.1–9.0 108 CD31 cells/kg). GVHD prophylaxis
consisted of cyclosporine (n5 71) or tacrolimus (n5 17), with (n5
20) or without (n 5 68) MTX, and 24 patients received additional
ATG (5–10 mg/kg, Fresenius). The median values of ALC on days
0, 7, 14, 21, and 28 were, respectively, 68 (0–1460), 229 (0–1320),
675 (0–3185), 601 (0–3357), and 662 (0–2016). The median fol-
low-up was 2 years (0.3–6.9). In the 36 patients whose ALC on day
0 was below 100, the proportion of patients who achieved complete
donor T-cell chimerism (.90%) on day 28 was significantly higher
than that of patients with ALC.100 (65% vs. 33%, p5 0.003). Pa-
tients whose ALC on day 0 was below 100 tended to show better OS
than those with a value above 100 (69% vs. 63% at 2 y, p 5 0.19).
Furthermore, 50 patients whose ALC on day 28 was above 600
tended to show higher probabilities of grade II-IV aGVHD (54%
vs. 34%, p 5 0.051) and cGVHD (52% vs. 37%, p 5 0.12) than
the remaining 38 patients. However, the rate of positive CMV anti-
genemia (60% vs. 50%), relapse rate (42% vs. 37%), and OS (67% vs.
68%) at 2 y were not significantly different according to ALC on day
28. In conclusion, low ALC on day 0 may become a surrogate marker
for effective host immune suppression resulting in higher donor T-
cell chimerism after busulfan-based RIST, and early recovery of
ALC on day 28 after RIST may predict GVHD, but not relapse or
OS.385
VIRAL INFECTIONS ARE THE GREATEST CAUSE OF INFECTIOUS MORTAL-
ITY AFTER CORD BLOOD (CB) TRANSPLANTATION (CBT) BUT THE MOR-
TALITY RISK IS LIMITED TO THE FIRST 4 MONTHS
Sauter, C., Abboud, M., Hawke, R.M., Heller, G., Scaradavou, A.,
Barker, J.N. Memorial Sloan-Kettering Cancer Center, New York, NY
As CBT is associated with prolonged neutropenia the infection
risk in the pre-engraftment period has received the most emphasis.
However, aggressive antimicrobial prophylaxis can be effective in
decreasing the lethality of bacterial and fungal infections whereas
viral infections remain challenging. We reviewed the incidence
of serious opportunistic infections (OI) in CBT recipients with
the hypothesis that viral infections pose the biggest infectious le-
thality risk. 52 patients [median 38 years (range 3–66); 12 AML,
12 ALL, 28 lymphoma] received myeloablative (MA, n 5 36) or
non-myeloablative (NMA, n 5 16) conditioning with cyclospor-
ine-A/ mycophenolate mofetil and GCSF. Double unit grafts (4-
6/6 HLA-A,B antigen, DRB1 allele matched to the patient) were
used to enhance engraftment. Serious OI were defined as severe
(required IV therapy/ admission), life-threatening, or fatal (caused
or contributed to death). The cumulative incidence (CI) of sus-
tained donor engraftment was 94% (95%CI:88–100) with the en-
grafting unit [1 6/6, 24 5/6, 23 4/6] having a median infused TNC
dose of 2.2  107/kg (range 1.3–5.3). The median neutrophil
recovery was 25 days (range 13–43) in MA and 11 days (range
7–36) in NMA recipients. The CI of grade II-IV acute graft-
vs-host disease (GVHD) at day 100 was 40% (95%CI:27–53)
and 6 patients have chronic GVHD to date. The day 180 trans-
plant-related mortality was 24% (95%CI:13–35) and the 1 year
overall survival is 64% (95%CI:52–80). The median CD41
count/microL (359–1570) at days 60, 120, 180 and 1 year were
188, 272, 375 and 570, respectively. The median phytohemagglu-
tinin (PHA) response (normal .92k) at these time points were
64k, 89k, 96k, and 140k, respectively. OIs by time-period are sum-
marized below. ‘‘Pneumonias’’ responded to combined anti-bacte-
rial/fungal therapy and the exact etiology was unknown. Viral
infections accounted for the greatest infectious mortality. In
contrast to bacterial/ fungal infections that diminished after day
30 viral infections continued to be a major problem in the post-
engraftment period. However, subsequently their incidence
decreased possibly related to immune recovery as suggested by
a median CD41 count .250/microL and PHA response .95%
the lower limit of normal by day 1120. In summary, the greatest
risk for infection-related death is due to viral infections. Improved
anti-viral agents and augmentation of anti-viral immunity should
be a major priority in CBT.Opportunistic Infections by Time Period
Time *Bacterial Fungal Viral Pneumonia TotalAdmit-30
(n552)19 (2 lethal) 9 (0 lethal) 16 (2 lethal)
(2 CMV;
9 HHV6;
4 BK; 1 Adeno)3 (0 lethal) 47 (4 lethal)131–60
(n548)11 (0 lethal) 1 (0 lethal) 15 (2 lethal)
(10 CMV;
1 HHV6; 3 BK;
1 Adeno)0 27 (2 lethal)161–120
(n541)4 (0 lethal) 1 (0 lethal) 6 (1 lethal)
(2 CMV;
1 Adeno; 1 RSV;
1 Influenza;
1 H. Zoster)1 (0 lethal) 12 (1 lethal)1121–180
(n533)3 (0 lethal) 0 4 (0 lethal)
(1 CMV;
1 EBV; 1 RSV;
1 Influenza)0 7 (0 lethal)1180–1 yr
(n521)1 (0 lethal) 0 3 (0 lethal)
(1 CMV; 2 EBV)0 4 (0 lethal)Total 38 (2 lethal) 11 (0 lethal) 44 (5 lethal) 4 (0 lethal) 97 (7 lethal)386
CHIMERISM DETECTION IN HEMATOPOIETIC CELL TRANSPLANT RECIP-
IENTS BY REAL-TIME QUANTITATIVE PCR (Q-PCR) VS. SHORT TANDEM
REPEAT (STR) ANALYSIS
Senitzer, D.1, Zhou, Y.1, Gaidulis, L.1, Lazaruk, K.2 1City of Hope Na-
tional Medical Center, Duarte, CA; 2Celera, San Francisco, CA
STR is now being routinely used for chimerism detection in HCT.
However, the sensitivity (\5%), multiplex PCR competition, and
stutter band artifacts complicate quantitative analysis. We have eval-
uated a real-time quantitative PCR (Q-PCR)method for chimerism
detection, and compared it with STR analyses. The ABI
AmpFLSTR Identifiler Kit with 15 allelic markers was used for
the STR chimerism study. Q-PCR procedure includes screening
with 34 polymorphic markers to identify informative loci, followed
by quantitation of the informative loci. The percentage of recipient
chimerism is calculated based on the cycle threshold (Ct) value. To
determine the accuracy of the Q-PCR method, fifty one peripheral
blood, bone marrow, and cell subset samples from related and unre-
lated transplant cases were compared. The difference of the % recip-
ient between Q-PCR and STR is listed in Table 1. To summarize,
8% of the Q-PCR data are exactly the same as the STR data; 86%
have less than a 5% difference and 6% have less than a 10% differ-
ence. The sensitivity of the Q-PCR assay can reach 0.1% based on
our serial dilution study. The specificity of the Q-PCR is 100%
based on a 20 sample study. Both within run precision and between
run precision of the Q-PCR are less than 10%. The variant amplifi-
cation efficacy of each primer set in the multiplex STR contributes to
the lower accuracy. Q-PCR eliminates the multiplex feature, and
quantifies data with internal calibration. Q-PCR chimerism assay
gives a high dynamic detection range from less than 0.1% to
100%. This advantage can be very useful in early detection of re-
lapse. Ease of operation, and automated data analysis is a further ad-
vantage of Q-PCR, resulting in significant saving in labor costs . In
conclusion, Q-PCR is a simple, fast, sensitive, and accurate assay for
detection and quantitation of chimerism in HCT recipients.Table 1. Chimerism Analysis By Q-PCR vs. STR
% Difference Between
Q-PCR & STR ASHI Related Unrelated Total %0.0 2 0 2 4 8
0.1-5.0 11 11 22 44 86
5.1-10.0 1 1 1 3 6
Total 14 12 25 51 100
